Sigilon Therapeutics' Fabry Disease Therapy Receives Orphan Drug Designation In US
- The FDA has designated Orphan Drug Status to Sigilon Therapeutics Inc's (NASDAQ: SGTX) SIG-007 to treat Fabry disease.
- It is a rare genetic disorder caused by AGAL deficiency and the accumulation of specific substrates within a patient's cells, contributing to multi-organ complications.
- SIG-007 comprises genetically modified cells with a non-viral vector to express human alpha-galactosidase A or AGAL.
- Among the benefits of Orphan Drug designation in the U.S. is seven years of market exclusivity for the indication, if approved.
- Price Action: SGTX shares closed 19.5% lower at $21.86 on Thursday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Fabry diseaseBiotech News Health Care Small Cap FDA General
